&nbsp;

Aug 2025

Drug

iBRUtinib

Other Name(s): Imbruvica®

Quick Link(s):

Aug 2025

Drug

venetoclax

Other Name(s): Venclexta®

Quick Link(s):

Aug 2025

Regimen

ENZL

Cancer Type:

Genitourinary,

Prostate

Intent: Curative, Palliative

Funding:

Exceptional Access Program

enzalutamide - For the treatment of metastatic castrate-resistant prostate cancer (mCRPC), based on criteria

Exceptional Access Program

enzalutamide - For the treatment of high risk non-metastatic castration-resistant prostate cancer (nmCRPC), based on criteria

Exceptional Access Program

enzalutamide - For the treatment metastatic castration-sensitive prostate cancer (mCSPC), based on criteria

Exceptional Access Program

enzalutamide - For the treatment of patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk of metastasis (high-risk BCR), based on criteria

Drugs Used:

enzalutamide

Quick Link(s):

Regimen Monograph

Aug 2025

Regimen

IBRUVENE

Cancer Type:

Hematologic,

Leukemia - Chronic Lymphocytic (CLL)

Intent: Palliative

Funding:

Exceptional Access Program

iBRUtinib - For the treatment of patients with chronic lymphocytic leukemia (CLL), in combination with venetoclax, based on criteria

Exceptional Access Program

venetoclax - For the treatment of patients with chronic lymphocytic leukemia (CLL), in combination with ibrutinib, based on criteria

Drugs Used:

iBRUtinib,

venetoclax

Quick Link(s):

Regimen Monograph

Aug 2025

Regimen

BORTDEXADARA

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - Relapsed or Refractory Multiple Myeloma

New Drug Funding Program

Daratumumab - In Combination with Bortezomib and Dexamethasone for Relapsed Multiple Myeloma

ODB - General Benefit

dexamethasone

Drugs Used:

Quick Link(s):

Regimen Monograph, Patient Info Sheet

Updated

Aug 2025

Regimen

BORTDEXADARA(SC)

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Bortezomib - Relapsed or Refractory Multiple Myeloma

New Drug Funding Program

Daratumumab - In Combination with Bortezomib and Dexamethasone for Relapsed Multiple Myeloma

ODB - General Benefit

dexamethasone

Drugs Used:

daratumumab (subcut),

bortezomib,

dexamethasone

Quick Link(s):

Regimen Monograph, Patient Info Sheet

Updated

Aug 2025

Drug

teclistamab

Other Name(s): Tecvayli®

Quick Link(s):

Jul 2025

Drug

sacituzumab govitecan

Other Name(s): Trodelvy®

Quick Link(s):

Jul 2025

Regimen

DEXAPOMA+BELA

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

ODB - General Benefit

dexamethasone

Drugs Used:

belantamab mafodotin (Compassionate),

pomalidomide (Unfunded),

dexamethasone

Quick Link(s):

Regimen Monograph

Aug 2025

Drug

glofitamab

Other Name(s): Columvi®

Quick Link(s):

Updated

Aug 2025

Regimen

GLOF; GLOF(RAMP)

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's High Grade,

Lymphoma - Non-Hodgkin's Intermediate Grade

Intent: Palliative

Funding:

New Drug Funding Program

Glofitamab (Outpatient) - Relapsed or Refractory Diffuse Large B-cell Lymphoma

High Cost Therapy Funding Program

Glofitamab (Inpatient) - Relapsed or Refractory Diffuse Large B-cell Lymphoma

Drugs Used:

oBINutuzumab,

glofitamab